Our results show that there is no difference between temperature-based myocardial protection strategy with conventional intermittent cardioplegia delivery.
In a prospective phase II Food and Drug Administration trial, robotic mitral valve repairs were performed in 112 patients at 10 centers by using the da Vinci surgical system.
In some instances, when there is a lack of evidence, or faulty interpretation of the evidence, clinical judgement should inform the application of EBM.
